|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Interest bearing deposits held in other financial institutions | ||||||||||||||||||||
| Debt securities available for sale, at fair value | ||||||||||||||||||||
| Debt securities held to maturity, at amortized cost (fair value $350,947 and $373,568) | ||||||||||||||||||||
| Loans, net of allowance of $1,746,371 and $1,708,269, respectively | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Foreclosed assets (OREO), net | ||||||||||||||||||||
| Investment in restricted stock, at cost | ||||||||||||||||||||
| Cash surrender value life insurance | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity: | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Non-interest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Paycheck protection program lending facility (PPPLF) funding | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Federal Home Loan Bank (FHLB) advances | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Common stock, $.01 par value, 20,000,000 shares authorized, 3,014,207 and 2,938,698 outstanding shares issued and outstanding at June 30, 2026 and 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Unearned ESOP shares, at cost | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
